Potomac Fund Management Inc. ADV Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Potomac Fund Management Inc. ADV acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,354 shares of the biopharmaceutical company's stock, valued at approximately $1,788,000. Gilead Sciences comprises approximately 1.6% of Potomac Fund Management Inc. ADV's portfolio, making the stock its 9th biggest holding.

Several other hedge funds have also modified their holdings of GILD. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at about $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by insiders.

Remove Ads

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.50 on Thursday, reaching $112.39. 10,041,148 shares of the company's stock were exchanged, compared to its average volume of 7,317,884. The business's 50-day moving average is $106.63 and its two-hundred day moving average is $95.52. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market capitalization of $139.94 billion, a price-to-earnings ratio of 303.76, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.81%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 11th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.